See more : Inner Mongolia Xingye Mining Co., Ltd. (000426.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Lyell Immunopharma, Inc. (LYEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lyell Immunopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Alrov Properties and Lodgings Ltd. (ALRPR.TA) Income Statement Analysis – Financial Results
- Synergia Energy Ltd (OEX.L) Income Statement Analysis – Financial Results
- Pulstec Industrial Co., Ltd. (6894.T) Income Statement Analysis – Financial Results
- Bénéteau S.A. (BTEAF) Income Statement Analysis – Financial Results
- GWG Holdings, Inc. (GWGHQ) Income Statement Analysis – Financial Results
Lyell Immunopharma, Inc. (LYEL)
About Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 130.00K | 84.68M | 10.65M | 7.76M | 657.00K |
| Cost of Revenue | 0.00 | 16.47M | 14.54M | 7.48M | 0.00 |
| Gross Profit | 130.00K | 68.22M | -3.89M | 281.00K | 657.00K |
| Gross Profit Ratio | 100.00% | 80.55% | -36.48% | 3.62% | 100.00% |
| Research & Development | 182.95M | 159.19M | 138.69M | 182.24M | 63.60M |
| General & Administrative | 66.98M | 117.31M | 89.06M | 46.88M | 39.15M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 66.98M | 117.31M | 89.06M | 46.88M | 39.15M |
| Other Expenses | -2.79M | 1.89M | -2.32M | -9.43M | -35.41M |
| Operating Expenses | 247.14M | 276.50M | 225.43M | 219.69M | 102.75M |
| Cost & Expenses | 247.14M | 276.50M | 225.43M | 219.69M | 102.75M |
| Interest Income | 23.45M | 7.05M | 1.17M | 5.94M | 8.12M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 20.25M | 16.47M | 14.54M | 7.48M | 4.38M |
| EBITDA | -226.76M | -166.65M | -199.94M | -207.64M | -100.83M |
| EBITDA Ratio | -174,429.23% | -194.96% | -1,546.53% | -2,677.19% | -15,347.49% |
| Operating Income | -247.01M | -183.12M | -214.78M | -211.94M | -102.09M |
| Operating Income Ratio | -190,006.15% | -216.24% | -2,016.68% | -2,732.56% | -15,538.66% |
| Total Other Income/Expenses | 12.38M | 3.84M | -36.65M | 7.47M | -27.29M |
| Income Before Tax | -234.63M | -183.12M | -250.22M | -204.47M | -129.38M |
| Income Before Tax Ratio | -180,486.15% | -216.24% | -2,349.47% | -2,636.31% | -19,692.09% |
| Income Tax Expense | 0.00 | -178.36M | 35.28M | -5.94M | -8.12M |
| Net Income | -234.63M | -4.75M | -285.50M | -198.53M | -121.26M |
| Net Income Ratio | -180,486.15% | -5.61% | -2,680.76% | -2,559.73% | -18,456.01% |
| EPS | -0.93 | -0.02 | -1.18 | -0.81 | -0.49 |
| EPS Diluted | -0.93 | -0.02 | -1.18 | -0.81 | -0.49 |
| Weighted Avg Shares Out | 250.98M | 247.08M | 242.74M | 246.58M | 246.58M |
| Weighted Avg Shares Out (Dil) | 250.98M | 247.08M | 242.74M | 246.58M | 246.58M |
3 Red Hot Penny Stocks To Watch Before Next Week, Time To Buy?
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
Lyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue Estimates
Lyell Immunopharma (LYEL) Reports Q4 Loss, Tops Revenue Estimates
Lyell Immunopharma (LYEL) Loses 21.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Lyell Immunopharma (LYEL) Expected to Beat Earnings Estimates: Should You Buy?
Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Wall Street Analysts Believe Lyell Immunopharma (LYEL) Could Rally 91%: Here's is How to Trade
Biotech ETF Tops in June: 5 Stocks That Outperform
Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports